CLINICAL TRIAL

Non-euploid embryo transfer for Aneuploidy

Recruiting · 18 - 65 · Female · Sunnyvale, CA

This study is evaluating whether embryos that are reported to be abnormal by preimplantation genetic testing result in liveborn infants.

See full description

About the trial for Aneuploidy

Eligible Conditions
Mosaicism · Aneuploidy

Treatment Groups

This trial involves 2 different treatments. Non-euploid Embryo Transfer is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Non-euploid embryo transfer
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Euploid Transfer
OTHER

Eligibility

This trial is for female patients between 18 and 65 years old. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Available aneuploid or mosaic embryos
No embryos available for transfer. show original
Willing to travel to Stanford for treatment
You have good English language fluency.\n show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 4 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 4 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Non-euploid embryo transfer will improve 1 primary outcome and 3 secondary outcomes in patients with Aneuploidy. Measurement will happen over the course of 7 years 3 months.

Pediatric Development
7 YEARS 3 MONTHS
Number of newborns and children who have abnormal pediatric development at 3 months, 2 years and 5 years following birth
7 YEARS 3 MONTHS
Pregnancy Rate
3 YEARS
Number participants who undergo embryo transfers that lead to a positive pregnancy test
3 YEARS
Live birth rate
4 YEARS
Number participants who conceive after embryo transfer and have a live birth.
4 YEARS
Obstetric complications
4 YEARS
Number of participants who have a maternal of fetal complication after embryo transfer
4 YEARS

Who is running the study

Principal Investigator
R. B. L.
Prof. Ruth Bunker Lathi, Professor
Stanford University

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get aneuploidy a year in the United States?

About 1.3 million people are diagnosed with an aneuploidy in the United States a year. About 80% of patients who have aneuploidy have a normal blood-test result, and these patients have a low risk of inheriting an additional genetic disorder; thus, most individuals probably don’t need genetic screening.

Anonymous Patient Answer

What are common treatments for aneuploidy?

Results from a recent clinical trial adds to the already existing evidence on common treatment therapies for aneuploidy. The list of treatment therapies for aneuploidy is relatively small compared to other conditions and disorders. Further study into the specifics of these treatments is needed.

Anonymous Patient Answer

Can aneuploidy be cured?

Many individuals have chromosome abnormalities that result in an abnormal karyotype and hence an abnormal set of numerical and structural chromosome genes. These may be responsible for some of the clinical features of aneuploidy. Because these abnormalities are often inherited, most individuals with aneuploidy have a normal life span and their phenotype is often mild compared with syndromes caused by mutations in the chromosome sets. Even without clinical signs of aneuploidy, individuals with chromosome abnormalities have a higher prevalence of many genetic and physical disabilities. These disabilities can be a lifelong issue for individuals with chromosome abnormalities, even without clinical signs of aneuploidy and even in the absence of any of the symptoms of an aneuploidy syndrome.

Anonymous Patient Answer

What are the signs of aneuploidy?

The signs and symptoms of aneuploidy vary, depending on the cause. In some cases, there are more complaints from patients, with the presence of more signs, compared with patients without aneuploidy.

Anonymous Patient Answer

What causes aneuploidy?

Abnormal numbers of chromosomes do not necessarily lead to abnormal functioning—it is possible for these abnormalities to occur without any ill effects. This is probably the case with trisomy of chromosome 21, in the case of Down syndrome, since people with this condition usually are of normal intelligence and do not have the characteristic features of severe brain-damaged people with autism. However, people with tetrasomy of chromosome 14, which often causes intellectual disability, are often affected by brain damage and often die in childhood.

Anonymous Patient Answer

What is aneuploidy?

In most cases, aneuploidy is a non-inherited and non-symptomatic disorder. It can be caused by a number of other processes, and in fact seems to be very common. Therefore, aneuploidy is not just a disease entity, but it will need integrated diagnosis, diagnosis, therapy, and even follow up in order to have a better comprehension of its clinical relevance, progression and prognosis. Aneuploidy is the general term and most of its subtypes are well-defined to have more reliable diagnoses and treatments.

Anonymous Patient Answer

Has non-euploid embryo transfer proven to be more effective than a placebo?

Contrary to common beliefs, our study supports the hypothesis that, for ET-cycles, aneuploidy of oocytes and embryo(s) has no positive effect and in contrast is associated with reduced pregnancy and clinical pregnancy rates.

Anonymous Patient Answer

What is non-euploid embryo transfer?

A lower number of embryos retrieved at the time of fertilization is required for those euploid embryos that are transferred as compared with those discarded. This is probably due to both an increased implantation rate and decreased post-fertilization mortality. A policy of embryo transfer only in response to clinical pregnancy offers an efficient use of embryonic resources.

Anonymous Patient Answer

Is non-euploid embryo transfer typically used in combination with any other treatments?

We found no evidence that aneuploid embryos are implanted more frequently in response to adjuvant treatments. For non-complicated IVF-ET, when the embryo scores higher than day 3/4 quality, the resulting pregnancy and implantation rates do not appear to be better than those for those embryos scoring 3/4.

Anonymous Patient Answer

Have there been any new discoveries for treating aneuploidy?

The development of techniques and screening-based approaches to treat aneuploidy has resulted in [an] increased use of therapeutic strategies for treating aneuploidy. It is necessary for patients to become informed regarding these new developments.

Anonymous Patient Answer

What is the latest research for aneuploidy?

The detection and classification of aneuploidy can be a useful tool for identifying candidates for more severe defects that can result in adverse perinatal outcomes, such as trisomy 21 (Down syndrome) or trisomy 18 (Edwards syndrome). The best method to detect aneuploidies is flow cytometry by looking at all chromosomes and at all their banding patterns. However, this technique can be difficult and laborious because it may take up to 2 weeks to complete; it uses a lot of equipment and has a high associated cost; it has a low positive predictive value; and it could be inaccurate if there is a lot of mosaicism or if there are structural and numerical chromosome rearrangements.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Aneuploidy by sharing your contact details with the study coordinator.